These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16493220)

  • 1. Comparison of urinary proteins in calcium stone formers and healthy individuals: a case-control study.
    Pourmand G; Nasseh H; Sarrafnejad A; Mojtahedi A; Mehrsai A; Alamdari DH; Nourijelyani K
    Urol Int; 2006; 76(2):163-8. PubMed ID: 16493220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Tamm-Horsfall protein and citrate: a case-control study of inhibitors and promoters of calcium stone formation.
    Pourmand G; Nasseh H; Sarrafnejad A; Mehrsai A; Hamidi Alamdari D; Nourijelyani K; Shekarpour L
    Urol J; 2005; 2(2):79-85. PubMed ID: 17629875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M; Shakhssalim N; Basiri A; Miladipour AH; Golestan B; Mohammadi Torbati P; Azadvari M; Eftekhari S
    Urol J; 2011; 8(2):99-106. PubMed ID: 21656467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in 24-hour urine composition between apatite and brushite stone formers.
    Moreira DM; Friedlander JI; Hartman C; Elsamra SE; Smith AD; Okeke Z
    Urology; 2013 Oct; 82(4):768-72. PubMed ID: 23791217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of urinary zinc and copper on calcium oxalate stone formation.
    Ozgurtas T; Yakut G; Gulec M; Serdar M; Kutluay T
    Urol Int; 2004; 72(3):233-6. PubMed ID: 15084769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical studies of the recurrence of urolithiasis (4). Crystal formation in urine and stone recurrence].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1988 Sep; 34(9):1543-7. PubMed ID: 3213790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between body mass index, lipid profiles, and types of urinary stones.
    Inci M; Demirtas A; Sarli B; Akinsal E; Baydilli N
    Ren Fail; 2012; 34(9):1140-3. PubMed ID: 22889148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test.
    Voss S; Hesse A; Zimmermann DJ; Sauerbruch T; von Unruh GE
    J Urol; 2006 May; 175(5):1711-5. PubMed ID: 16600737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using 24-hour urinalysis to predict stone type.
    Moreira DM; Friedlander JI; Hartman C; Elsamra SE; Smith AD; Okeke Z
    J Urol; 2013 Dec; 190(6):2106-11. PubMed ID: 23764079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary metabolic evaluation of stone formers-a Malaysian perspective.
    Hong YH; Dublin N; Razack AH; Mohd MA; Husain R
    Urology; 2012 Sep; 80(3):529-34. PubMed ID: 22578827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium phosphate crystal-associated proteins: alpha2-HS-glycoprotein, prothrombin F1, and osteopontin.
    Nishio S; Hatanaka M; Takeda H; Aoki K; Iseda T; Iwata H; Yokoyama M
    Mol Urol; 2000; 4(4):383-90. PubMed ID: 11156706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dietary control for out-patients in urinary stone clinic].
    Kato T; Yanagawa M; Hioki T; Sakurai M; Yamakawa K; Araki T; Yamamoto I; Arima K; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1993 Jul; 39(7):593-8. PubMed ID: 8362676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cellular oxalate in oxalate clearance of patients with calcium oxalate monohydrate stone formation and normal controls.
    Oehlschläger S; Fuessel S; Meye A; Herrmann J; Froehner M; Albrecht S; Wirth MP
    Urology; 2009 Mar; 73(3):480-3. PubMed ID: 19167040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal oxalate excretion following oral oxalate load in patients with urinary calculus disease and healthy controls].
    Ebisuno S; Morimoto S; Yoshida T; Fukatani T; Yasukawa S; Okawa T
    Hinyokika Kiyo; 1986 Dec; 32(12):1773-9. PubMed ID: 3825824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the presence of abnormal proteins in the urine of recurrent stone formers.
    Grover PK; Resnick MI
    J Urol; 1995 May; 153(5):1716-21. PubMed ID: 7715017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.